Editorial comment

The treatment options for metastatic prostate cancer have increased dramatically over the past decade, including novel hormonal therapies, chemotherapies, and radiopharmaceuticals. The administration of myelosuppressive chemotherapies has generally been supervised by medical oncologists in the United States. The oversight of oral agents such as abiraterone  + prednisone (abi) and enzalutamide (enza) has been less well defined. This issue of the Gold Journal describes the increasing role of urologists in prescribing these agents.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research